Xiangxue Pharmaceutical (300147) — Financial Flexibility Index
Xiangxue Pharmaceutical (300147) has a Financial Flexibility Index of 0.01x as of September 2025. Free cash flow of CN¥81.38 Million (operating CF CN¥75.64 Million minus capex CN¥5.74 Million) represents 0% of total liabilities (CN¥6.27 Billion). Check total reinvestment intensity of Xiangxue Pharmaceutical to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Xiangxue Pharmaceutical Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Xiangxue Pharmaceutical across 19 annual periods. For the full cash flow conversion analysis, see Xiangxue Pharmaceutical cash flow conversion.
Annual Financial Flexibility Index for Xiangxue Pharmaceutical (2007–2025)
Year-by-year free cash flow to debt coverage for Xiangxue Pharmaceutical. Explore Xiangxue Pharmaceutical (300147) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | CN¥161.15 Million | CN¥139.63 Million | CN¥6.70 Billion | ▲ +172.8% |
| 2024 | 0.01x | CN¥53.42 Million | CN¥18.17 Million | CN¥6.06 Billion | ▼ -83.5% |
| 2023 | 0.05x | CN¥319.48 Million | CN¥263.44 Million | CN¥5.97 Billion | ▼ -41.2% |
| 2022 | 0.09x | CN¥594.65 Million | CN¥227.38 Million | CN¥6.53 Billion | ▼ -15.4% |
| 2021 | 0.11x | CN¥820.30 Million | CN¥257.56 Million | CN¥7.62 Billion | ▼ -38.4% |
| 2020 | 0.17x | CN¥964.60 Million | CN¥257.18 Million | CN¥5.53 Billion | ▲ +2.1% |
| 2019 | 0.17x | CN¥744.11 Million | CN¥83.02 Million | CN¥4.35 Billion | ▲ +34.5% |
| 2018 | 0.13x | CN¥586.70 Million | CN¥91.24 Million | CN¥4.61 Billion | ▼ -20.4% |
| 2017 | 0.16x | CN¥887.40 Million | CN¥109.53 Million | CN¥5.56 Billion | ▼ -68.2% |
| 2016 | 0.50x | CN¥2.16 Billion | CN¥198.48 Million | CN¥4.30 Billion | ▲ +27.3% |
| 2015 | 0.39x | CN¥436.84 Million | CN¥159.89 Million | CN¥1.11 Billion | ▲ +65.6% |
| 2014 | 0.24x | CN¥409.43 Million | CN¥165.58 Million | CN¥1.72 Billion | ▼ -35.0% |
| 2013 | 0.37x | CN¥646.92 Million | CN¥328.37 Million | CN¥1.76 Billion | ▼ -3.6% |
| 2012 | 0.38x | CN¥537.03 Million | CN¥118.91 Million | CN¥1.41 Billion | ▼ -26.6% |
| 2011 | 0.52x | CN¥260.24 Million | CN¥29.55 Million | CN¥502.16 Million | ▲ +141.1% |
| 2010 | 0.21x | CN¥102.33 Million | CN¥45.47 Million | CN¥476.01 Million | ▼ -21.7% |
| 2009 | 0.27x | CN¥99.04 Million | CN¥46.19 Million | CN¥360.69 Million | ▼ -49.6% |
| 2008 | 0.54x | CN¥193.44 Million | CN¥55.72 Million | CN¥354.94 Million | ▼ -30.2% |
| 2007 | 0.78x | CN¥282.75 Million | CN¥138.02 Million | CN¥361.98 Million | — |